Details for New Drug Application (NDA): 062586
✉ Email this page to a colleague
NDA 062586 describes ERYTHROCIN, which is a drug marketed by Abbott, Hospira, and Azurity, and is included in five NDAs. It is available from one supplier. Additional details are available on the ERYTHROCIN profile page.
The generic ingredient in ERYTHROCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
The generic ingredient in ERYTHROCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 062586
| Tradename: | ERYTHROCIN |
| Applicant: | Abbott |
| Ingredient: | erythromycin lactobionate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Jan 4, 1988 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Jan 4, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
